Did You Know?

Editor’s Picks

Latest News

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial...

RIVANNA secures $800,000 Virginia Catalyst Grant alongside matching funds to advance AI-enabled ultrasound platform for neuraxial anesthesia

CHARLOTTESVILLE, Va., Aug. 14, 2025 /PRNewswire/ -- RIVANNA®, developers of world-first imaging-based medical technologies, was recently awarded grant funding valued...

error: Content is protected !!